Dosage and usage of ADAMTS13 recombinant protease (trade name: Apadase α, English: Adzynma)

Adzynma (apadaseα) is a recombinant ADAMTS13 protease indicated for the treatment of congenitalthrombotic thrombocytopenic purpura (cTTP). cTTP is a rare genetic disease in which mutations in the ADAMTS13 gene lead to a lack of functional ADAMTS13 protease in patients, leading to microvascular thrombosis, thrombocytopenia, and hemolytic anemia. Adzynma helps restore normal coagulation function, reduce the risk of thrombosis, and improve patients' clinical symptoms by replenishing missing enzyme activity. The drug is indicated for use in both adult and pediatric patients as a preventive treatment or as an as-needed treatment during an acute episode.

Adzynma is for intravenous use only and must be administered after reconstitution. Each vial is labeled with the actual rADAMTS13 activity expressed in international units (IU). When calculating the dose to be administered, the actual potency marked on the vial must be used rather than the nominal potency to ensure accurate dosing. For pediatric patients, the dosing regimen is the same as for adults, with dose adjustments based on body weight. Specific drug preparation and infusion methods should strictly follow the complete prescription instructions to ensure safety and effectiveness.

In preventive treatment, adult and pediatric patients are usually given an intravenous infusion every other week at a dose of 40 IU/kg of body weight at a rate of 2 to 4 ml per minute. Based on the patient's clinical response or previous preventive dosing, doctors may adjust the dosing frequency, for example, increasing it to 40 IU/kg once a week, to better maintain ADAMTS13 activity levels and prevent disease flare-ups.

For on-demand treatment of acute attacks, Adzynma’s dosing schedule is divided into different phases. On the first day of treatment, patients received an initial dose of 40 IU/kg body weight to rapidly increase enzyme activity and inhibit thrombosis. The next day, the dose was adjusted to 20 IU/kg to continue to stabilize the condition. Starting on the third day and until two days after complete resolution of the acute event, the maintenance dose is 15 IU/kg. The infusion rate of all on-demand treatments is also controlled at 2 to 4 ml per minute to ensure smooth entry of the drug into the blood circulation and reduce the risk of adverse reactions.

Adzynma's individualized dosing regimen needs to be adjusted based on the patient's weight, clinical status and treatment response. Physicians should closely monitor patients' ADAMTS13 activity levels, platelet counts, and hemolysis indicators to optimize treatment effects. Reasonable dosage and standardized infusion management are crucial to improve drug efficacy and reduce complications, so that cTTP patients can obtain better long-term prognosis.

Reference link:https://www.drugs.com/adzynma.html